Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study

Area of Science:

• Endocrinology
• Pulmonology
• Pharmacology

Background:

• Asthma exacerbations often require hospitalization and can be linked to various physiological changes.
• Adrenal function is crucial for managing stress responses, particularly during severe illness.
• Corticosteroid therapy, common in asthma management, is known to potentially suppress the hypothalamic-pituitary-adrenal axis.

Purpose of the Study:

• To investigate adrenal function in patients hospitalized with severe bronchospasm.
• To assess the correlation between dehydroepiandrosterone sulphate (DHEA-SO4) levels and asthma severity or steroid use.
• To determine if low DHEA-SO4 levels indicate adrenal suppression in this patient population.

Main Methods:

• Measurement of dehydroepiandrosterone sulphate (DHEA-SO4) levels in 72 hospitalized asthma patients.
• Comparison of DHEA-SO4 levels against a reference range (lower limit 700 micrograms/l).
• Analysis of DHEA-SO4 levels in relation to oral steroid therapy, inhaled steroid use, and no steroid therapy.

Main Results:

• A significant proportion of hospitalized asthma patients (40%) exhibited low DHEA-SO4 levels (<700 micrograms/l).
• Low DHEA-SO4 levels were observed in 10/14 patients on oral steroids, 8/23 on inhaled steroids, and 6/29 on no known steroid therapy.
• Five of six patients with recent oral steroid use within a month of admission also showed low DHEA-SO4 values.

Conclusions:

• Low dehydroepiandrosterone sulphate (DHEA-SO4) levels suggest possible adrenal suppression in a substantial number of severe asthma patients.
• These findings highlight the need to consider adrenal function in asthmatic patients, especially those on or recently treated with corticosteroids.
• DHEA-SO4 measurement may serve as a useful indicator for assessing adrenal function in severe asthma exacerbations.